0001209191-23-048845.txt : 20230908 0001209191-23-048845.hdr.sgml : 20230908 20230908190027 ACCESSION NUMBER: 0001209191-23-048845 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230907 FILED AS OF DATE: 20230908 DATE AS OF CHANGE: 20230908 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SCHEGERIN MARC CENTRAL INDEX KEY: 0001773184 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38940 FILM NUMBER: 231246413 MAIL ADDRESS: STREET 1: ARQULE INC STREET 2: 1 WALL ST FL6 CITY: BURLINGTON STATE: MA ZIP: 01803 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Morphic Holding, Inc. CENTRAL INDEX KEY: 0001679363 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473878772 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 GATEHOUSE DRIVE A2 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 9787296480 MAIL ADDRESS: STREET 1: 35 GATEHOUSE DRIVE A2 CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Morphic Holding, LLC DATE OF NAME CHANGE: 20160712 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-09-07 0 0001679363 Morphic Holding, Inc. MORF 0001773184 SCHEGERIN MARC C/O MORPHIC HOLDING, INC. 35 GATEHOUSE DRIVE, A2 WALTHAM MA 02451 0 1 0 0 CFO and COO 0 Common Stock 2023-09-07 4 M 0 20000 15.00 A 44136 D Common Stock 2023-09-07 4 S 0 6691 53.2004 D 37445 D Common Stock 2023-09-07 4 S 0 13309 54.9166 D 24136 D Stock Option (right to buy Common Stock) 15.00 2023-09-07 4 M 0 20000 0.00 D 2030-04-05 Common Stock 20000 57268 D Includes 396 shares of Common Stock acquired under the Issuer's employee stock purchase plan on February 28, 2022. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person dated June 28, 2022. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 to $53.73 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.19 to $55.10 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option vested as to 25% of the total shares on April 6, 2021, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vested and exercisable on April 6, 2024, subject to the reporting person's provision of service to the Issuer on each vesting date. /s/ Robert Farrell as attorney-in-fact for Marc Schegerin 2023-09-08